• Publications
  • Influence
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
  • S. Qin, Y. Bai, Yan Sun
  • Medicine, Biology
    Journal of clinical oncology : official journal…
  • 1 October 2013
TLDR
Although the study did not meet its primary end point, the trend toward improved OS with FOLFOX4, along with increased PFS and RR, suggests that this regimen may confer some benefit to Asian patients, but an OS benefit cannot be concluded from these data.
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial
TLDR
Among the Chinese patients in this trial, anlotinib appears to lead to prolonged overall survival and progression-free survival, suggesting that anlot inib is well tolerated and is a potential third-line or further therapy for patients with advanced NSCLC.
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
  • A. Wolff, A. Lazar, D. Hayes
  • Medicine, Biology
    Journal of clinical oncology : official journal…
  • 10 January 2013
TLDR
Adding temsirolimus to letrozole did not improve PFS as first-line therapy in patients with AI-naive advanced breast cancer, and exploratory analyses of benefit in younger postmenopausal patients require external confirmation.
[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].
  • Jinwan Wang, Yan Sun, C. Yao
  • Medicine, Biology
    Zhongguo fei ai za zhi = Chinese journal of lung…
  • 20 August 2005
TLDR
The addition of YH-16 to NP regimen results in significantly and clinically meaningful improvement in response rate, median time to tumor progression, and clinical benefit rate compared with NP alone in advanced NSCLC patients.
...
1
2
3
4
5
...